Recent Developments

SOLVO is continuously expanding its product and service portfolio, with 10-20 new launches annually. Our focus is to develop new products and services based on the latest results in drug transporter science, the needs of the pharmaceutical industry and suggestion of the various regulatory agencies such as FDA and EMA regarding transporter related drug drug interaction studies. You can easily catch up with our latest developments by visiting this page which summarizes the newest offerings in our portfolio. Want our news on our latest developments delivered directly to your inbox?

Get the news automatically by subscribing via: Subscribe to RSS feed

Service and Product Launches

2020 Q3

The THTR1 and THTR2 transporter were made newly available in our portfolio!

  • P-gp are now available: PSC-833 (valspodar), verapamil and ketoconazole
  • BCRP are now available: Ko143, novobiocin, FTC

Additional inhibitors were characterized for P-gp (MDR1) and BCRP in Caco-2 and newly added to our portfolio!

Our Caco-2 assay has in addition to Estrone-3-sulfate now also bee characterized with sulfasalazine as BCRP probe substrate!

The BCRP assay was fully characterized with a clinically relevant substrate.

The dogSglt2 transporter was made newly available in our portfolio!

The mouseSglt2 transporter was made newly available in our portfolio!

The SGLT6 transporter was made newly available in our portfolio!

Human MDR1 was expressed into canine-P-gp knock-out MDCKII cells transfected and the cell line added newly to our portfolio!

The SGLT5 transporter was made newly available in our portfolio!

The OAT1, OAT3 and OAT4 assays were fully characterized with a clinically relevant substrates and newly added to our portfolio.

2020 Q2

The LAT1 transporter was made newly available in our portfolio!

The NIS transporter was made newly available in our portfolio!

The OCT1 assay was fully characterized with a clinically relevant substrate and newly added to our portfolio.

2020 Q1

The OATP1B1 assay was fully characterized with a clinically relevant substrate and newly added to our portfolio.

The OATP1B3 assay was fully characterized with a clinically relevant substrate and newly added to our portfolio.

The Caco-2 assay was set-up for testing MRP2 substrate CDCF-DA, confirming this Caco-2 clone has activity of MRP2.

2019 Q4

The MCT8 transporter was made newly available in our portfolio!

The MCT10 transporter was made newly available in our portfolio!

The rat Ntcp transporter was made newly available in our portfolio!

2019 Q3

The PREDICELL product line was updated for use of HEK293 cells expressing the transporters of interest, instead of CHO cells used previously in the product.

2019 Q2

The OATP1B1 assay was fully characterized with a clinically relevant substrate and newly added to our portfolio.

The OATP1B3 assay was fully characterized with a clinically relevant substrate and newly added to our portfolio.

2019 Q1

An improved, HEK293-derived cell line was developed to replace the historically used MDCKII-OATP2B1 cell line.

2018 Q4

The MRP1 assay was fully characterized with a well known substrate and newly added to our portfolio.

The MRP2 assay was fully characterized with a clinically relevant substrate and newly added to our portfolio.

2018 Q3

2018 Q2

2018-Q1

2017-Q4

2017-Q2

2017-Q1

2016-Q4

Vesicular Transport Membranes - Vesicular Transport Assays MRP2-HEK293, BCRP-HEK293 with Rosuvastatin

2016-Q3

2016-Q2

2016-Q1

2015-Q3

2015-Q2

2015-Q1

2014-Q4

2014-Q3

2014-Q2

2013-Q4

2013-Q3

2013-Q2

2013-Q1